Discontinued — last reported Q3 '22
This is a positive signal — lower values indicate better performance for this metric.
An increase indicates that the company has determined the assets in the Greater China segment are worth less than previously recorded, signaling potential challenges in market performance, competitive positioning, or regulatory environments. A stable or zero balance suggests that the segment's underlying business value remains intact relative to its acquisition cost.
This metric represents the cumulative total of impairment charges recognized against goodwill specifically allocated to...
Most multinational pharmaceutical companies report goodwill impairment at the segment or reporting unit level; peers often disclose this in the notes to the consolidated financial statements under 'Goodwill and Intangible Assets'.
vtrs_segment_greater_china_goodwill_impaired_accumulated_impairment_loss| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | |
|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |